Pharma BD Deal Intelligence
A resurrection deal: GSK's $66M-upfront, up to $591M license rescued tebipenem HBr after an FDA refuse-to-file, and the gamble paid off when the confirmatory PIVOT-PO Phase 3 stopped early for efficacy in May 2025 — though it took nearly three years to get there.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →GSK has agreed to pay Spero Therapeutics $66 million upfront and up to $525 million in milestones for an exclusive license to tebipenem HBr, a Phase…
GSK on Wednesday struck a licensing deal worth up to $591 million for tebipenem HBr, an oral antibiotic developed by Spero Therapeutics that could fill a…
GSK resubmitted the tebipenem HBr NDA to the FDA on Dec 19, 2025, triggering a $25 million milestone payment to Spero Therapeutics (expected Q1 2026). GSK…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
GSK signed an exclusive global license (ex-certain Asian territories, where Meiji retains rights) with Spero Therapeutics for tebipenem HBr, a late-stage oral carbapenem antibiotic for complicated urinary tract infections (cUTI) including acute pyelonephritis. GSK paid $66M upfront plus a $9M equity investment, with up to $525M in development and commercial milestones plus tiered royalties (headline value up to ~$591M). The deal, announced Sep 21, 2022 and closed Nov 7, 2022, revived a program that nearly collapsed after the FDA refused to file Spero's original NDA in 2021 and required a confirmatory Phase 3. That risk has since largely resolved: the confirmatory PIVOT-PO Phase 3 was stopped early for efficacy in May 2025 after an IDMC interim (n=1,690), and full data at IDWeek 2025 showed tebipenem non-inferior to IV imipenem-cilastatin (58.5% vs 60.2% overall success; adjusted difference -1.3%). GSK resubmitted the NDA on Dec 19, 2025 — triggering a $25M milestone to Spero (received Q1 2026) — and the FDA set a PDUFA target action date of Jun 18, 2026. If approved, tebipenem HBr would be the first oral carbapenem antibiotic in the US.
2 US cases/yr · $2.3B Global UTI antibiotics market (2022 base) · ~30-40% U.S. E. coli cUTI isolates with ESBL or fluoroquinolone resistance
Complicated urinary tract infection (cUTI) is a UTI complicated by structural or functional abnormality of the urinary tract or by host factors that predispose to persistent infection, treatment failure, or relapse - including indwelling catheters, obstruction, pregnancy, immunocompromise, kidney transplant, and acute pyelonephritis. The U.S. cUTI burden is approximately 2.8-3.0 million episodes per year with about 626,000 hospital admissions annually, and rising prevalence of multidrug-resistant gram-negative pathogens (ESBL-producing E. coli, fluoroquinolone-resistant uropathogens) is forcing reliance on intravenous carbapenems administered in inpatient or outpatient infusion settings. The unmet need driving the tebipenem opportunity is the absence of an oral carbapenem option in the United States: ESBL E. coli cUTI is the largest single resistance bucket where current oral options (fluoroquinolones, cephalosporins, fosfomycin, nitrofurantoin) have unacceptable failure rates, leaving IV ertapenem as the de facto standard and pushing roughly 40-50% of patients into hospital-based therapy that an oral pro-drug carbapenem could shift to home administration.
The cUTI competitive landscape is dense in IV but starved of oral options. Approved IV carbapenems include ertapenem (Invanz, Merck/MSD generics), meropenem (Merrem, AstraZeneca/generics), imipenem-cilastatin (Primaxin, Merck), and meropenem-vaborbactam (Vabomere, Melinta). Newer beta-lactam/beta-lactamase inhibitor combinations driving the cUTI/cIAI franchise include ceftolozane-tazobactam (Zerbaxa, Merck), ceftazidime-avibactam (Avycaz, AbbVie), cefiderocol (Fetroja, Shionogi), imipenem-relebactam (Recarbrio, Merck), and plazomicin (Zemdri, Achaogen/Cipla). On the oral side the landscape is much sparser - sulopenem (Iterum) was rejected by FDA in 2021 in uncomplicated UTI, fluoroquinolones face FDA black-box warnings limiting use, and fosfomycin is single-dose only. Tebipenem HBr would be the first FDA-approved oral carbapenem in the U.S. if the pivotal ADAPT-PO Phase 3 (which had hit non-inferiority vs IV ertapenem) yields a path forward; however the FDA had issued a Refusal to File / requested additional Phase 3 data ahead of the GSK transaction, creating the regulatory rationale for GSK absorbing development risk in exchange for the larger commercial prize.
Exclusive license for tebipenem HBr closed; $66M upfront + $9M equity, up to $525M milestones plus royalties.
IDMC recommended early stop for efficacy at a planned interim (n=1,690); tebipenem non-inferior to IV imipenem-cilastatin, no new safety concerns.
58.5% (261/446) success for oral tebipenem vs 60.2% (291/483) IV imipenem-cilastatin; adjusted difference -1.3% (95% CI -7.5, 4.8).
GSK resubmitted the tebipenem HBr NDA to FDA, triggering a $25M milestone to Spero (Q1 2026). FDA PDUFA target action date June 18, 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GSK plc / Spero Therapeutics, Inc. (this deal) | 2022 | $600M | — |
| GSK plc / SmithKline Beecham | 2000 | $12.0B | 79 |
| GSK plc / Pfizer Inc. | 2018 | $0.0M | 77 |
| GSK plc / Novartis AG | 2014 | $16.0B | 76 |
| GSK plc / Hansoh Pharmaceutical Group Co. Ltd. | 2023 | $1.7B | 74 |
| GSK plc / Nuvalent, Inc. | 2026 | $10.6B | 70 |
| GSK plc / Sierra Oncology Inc. | 2022 | $1.9B | 70 |
← Browse all deals · How we score deals
More: 2022 deals · GSK plc deals · Infectious Disease deals